Society of Nuclear Medicine Offers Online CME

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

RESTON, Virginia-The Society of Nuclear Medicine (SNM) has formed an online collaboration with Medscape, a website for health care professionals and consumers, to release an educational program highlighting key content from the SNM’s 2001 annual conference.

RESTON, Virginia—The Society of Nuclear Medicine (SNM) has formed an online collaboration with Medscape, a website for health care professionals and consumers, to release an educational program highlighting key content from the SNM’s 2001 annual conference.

This free CME program, available on Medscape (www.medscape.com), showcases scientific articles covering core topics of interest to nuclear medicine specialists and specialty physicians. The program has been approved for 2 Category 1 CME credits by the SNM.

In a separate news release, the Society announced that webcasts of sessions from the annual conference are available in the SNM Virtual Library, produced by DigiScript. The cost, including CME credits, is $25 for members and $40 for nonmembers. To subscribe, go to www.snm.org. 

Articles in this issue
Elderly Colon Cancer Patients Benefit From Adjuvant Chemotherapy
Stromal Cells May Be Involved in Development of Breast Carcinoma
Intercultural Facts About Cancer
Nurse-Provided Education Crucial to Sural Nerve Graft Prostatectomy Patients
18-Gene Cluster Found in ER-Positive Breast Cancers
Viread OK’d for Treating HIV With Other Antiretrovirals
Surgeons in New York Operate on Patient in France
Fulvestrant Reduces Cell Turnover Index More Than Tamoxifen
New Lung Cancer Campaign Launched
CPDR Updates Its Prostate Cancer Website
NIAID Begins Phase I Trial of a DNA-Based HIV Vaccine
PET Used to Measure Efficacy of an Angiogenesis Inhibitor
Avon Donates $20 Million to NCI for Cancer Research
Weekly Gemcitabine/Vinorelbine Proves Effective in NSCLC
Supplemental NDA Submitted for Gleevec
Recent Videos
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
2 KOLs are featured in this series
Related Content
The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.

SON-080 May Decrease Chemotherapy-Induced Peripheral Neuropathy

Ariana Pelosci
July 26th 2024
Article

The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

FDA Accepts Resubmitted BLA for Cosibelimab in Advanced Skin Cancer

Russ Conroy
July 26th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

ODAC Votes in Favor of New Perioperative NSCLC Trial Design Proposals

Russ Conroy
July 25th 2024
Article

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

Ozuriftamab Vedotin Gains FDA Fast Track Designation for Recurrent SCCHN

Roman Fabbricatore
July 25th 2024
Article

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.